160 related articles for article (PubMed ID: 38145575)
1. How I treat myeloproliferative neoplasms in pregnancy.
Robinson S; Ragheb M; Harrison C
Blood; 2024 Feb; 143(9):777-785. PubMed ID: 38145575
[TBL] [Abstract][Full Text] [Related]
2. Myeloproliferative neoplasms in adolescents and young adults.
Amerikanou R; Lambert J; Alimam S
Best Pract Res Clin Haematol; 2022 Jun; 35(2):101374. PubMed ID: 36333071
[TBL] [Abstract][Full Text] [Related]
3. How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy.
Robinson SE; Harrison CN
Br J Haematol; 2020 May; 189(4):625-634. PubMed ID: 32150650
[TBL] [Abstract][Full Text] [Related]
4. Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy.
Griesshammer M; Sadjadian P; Wille K
Expert Rev Hematol; 2018 Sep; 11(9):697-706. PubMed ID: 30084669
[TBL] [Abstract][Full Text] [Related]
5. Management of MPN beyond JAK2.
Harrison CN; Garcia NC
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):348-54. PubMed ID: 25696878
[TBL] [Abstract][Full Text] [Related]
6. Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregnancy.
Sant'Antonio E; Borsani O; Camerini C; Botta C; Santoro M; Allegra A; Siragusa S
Blood Rev; 2022 Mar; 52():100903. PubMed ID: 34742614
[TBL] [Abstract][Full Text] [Related]
7. Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms.
Guglielmelli P; Bartalucci N; Rotunno G; Vannucchi AM
Expert Rev Hematol; 2014 Aug; 7(4):423-5. PubMed ID: 24849893
[TBL] [Abstract][Full Text] [Related]
8. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases.
Harrison C
Br J Haematol; 2005 May; 129(3):293-306. PubMed ID: 15842653
[TBL] [Abstract][Full Text] [Related]
9. Essential Thrombocythemia and Post-Essential Thrombocythemia Myelofibrosis: Updates on Diagnosis, Clinical Aspects, and Management.
Puglianini OC; Peker D; Zhang L; Papadantonakis N
Lab Med; 2023 Jan; 54(1):13-22. PubMed ID: 35960786
[TBL] [Abstract][Full Text] [Related]
10. Management and outcomes of 27 pregnancies in women with myeloproliferative neoplasms.
Lapoirie J; Contis A; Guy A; Lifermann F; Viallard JF; Sentilhes L; James C; Duffau P
J Matern Fetal Neonatal Med; 2020 Jan; 33(1):49-56. PubMed ID: 29945475
[No Abstract] [Full Text] [Related]
11. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.
Mesa R; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Boyle J; Mascarenhas JO
BMC Cancer; 2016 Feb; 16():167. PubMed ID: 26922064
[TBL] [Abstract][Full Text] [Related]
12. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
[TBL] [Abstract][Full Text] [Related]
13. Bomedemstat as an investigative treatment for myeloproliferative neoplasms.
Rienhoff HY; Gill H
Expert Opin Investig Drugs; 2023; 32(10):879-886. PubMed ID: 37804041
[TBL] [Abstract][Full Text] [Related]
14. Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities.
Coltro G; Loscocco GG; Vannucchi AM
Int Rev Cell Mol Biol; 2021; 365():1-69. PubMed ID: 34756241
[TBL] [Abstract][Full Text] [Related]
15. Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Gerds AT; Gotlib J; Ali H; Bose P; Dunbar A; Elshoury A; George TI; Gundabolu K; Hexner E; Hobbs GS; Jain T; Jamieson C; Kaesberg PR; Kuykendall AT; Madanat Y; McMahon B; Mohan SR; Nadiminti KV; Oh S; Pardanani A; Podoltsev N; Rein L; Salit R; Stein BL; Talpaz M; Vachhani P; Wadleigh M; Wall S; Ward DC; Bergman MA; Hochstetler C
J Natl Compr Canc Netw; 2022 Sep; 20(9):1033-1062. PubMed ID: 36075392
[TBL] [Abstract][Full Text] [Related]
16. BCR::ABL1 negative myeloproliferative neoplasms: A review focused on essential thrombocythemia and polycythemia vera.
Khodier M; Gadó K
Physiol Int; 2023 Sep; 110(3):227-250. PubMed ID: 37651280
[TBL] [Abstract][Full Text] [Related]
17. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
Landgren O; Goldin LR; Kristinsson SY; Helgadottir EA; Samuelsson J; Björkholm M
Blood; 2008 Sep; 112(6):2199-204. PubMed ID: 18451307
[TBL] [Abstract][Full Text] [Related]
18. Impact of Myeloproliferative neoplasms on patients' employment status and work productivity in the United States: results from the living with MPNs survey.
Yu J; Parasuraman S; Paranagama D; Bai A; Naim A; Dubinski D; Mesa R
BMC Cancer; 2018 Apr; 18(1):420. PubMed ID: 29653557
[TBL] [Abstract][Full Text] [Related]
19. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
Deadmond MA; Smith-Gagen JA
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2131-8. PubMed ID: 25968903
[TBL] [Abstract][Full Text] [Related]
20. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
